{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
chloramphenicol palmitate
to a specific field?
Status:
Possibly Marketed Outside US
Source:
M006
(2024)
Source URL:
First approved in 2024
Source:
M006
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2020)
Source URL:
First approved in 2013
Source:
21 CFR 348
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2017)
Source URL:
First approved in 2011
Source:
M020
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
21 CFR 348
(2001)
Source URL:
First approved in 1953
Source:
NDA008762
Source URL:
Class:
POLYMER
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
US Previously Marketed
Source:
21 CFR 310.545(a)(24)(i) menstrual/diuretic corn silk
Source URL:
First approved in 2014
Source:
21 CFR 358H
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
US Previously Marketed
Source:
Spermaceti U.S.P.
(1921)
Source URL:
First marketed in 1921
Class:
STRUCTURALLY DIVERSE
Status:
First approved in 2004
Source:
21 CFR 358H
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
US Previously Marketed
Source:
SURFAXIN by LEES PHARM HK
(2012)
Source URL:
First approved in 2012
Source:
SURFAXIN by LEES PHARM HK
Source URL:
Class:
G1 SPECIFIED SUBSTANCE
Status:
Possibly Marketed Outside US
Source:
M020
(2025)
Source URL:
First approved in 2014
Source:
M016
Source URL:
Class:
G1 SPECIFIED SUBSTANCE
